Skip to main navigation
Skip to search
Skip to main content
Region Zealand Home
Help & FAQ
Link opens in a new tab
Dansk
English
Search content at Region Zealand
Home
Profiles
Research units
Projects
Research output
Prizes
Activities
Courses
Press/Media
Impacts
Treatment Responsiveness in KCNT1-Related Epilepsy
Mark P Fitzgerald
*
, Martina Fiannacca
, Douglas M Smith
, Tracy S Gertler
, Boudewijn Gunning
, Steffen Syrbe
, Nienke Verbeek
, Hannah Stamberger
, Sarah Weckhuysen
, Berten Ceulemans
, An-Sofie Schoonjans
, Massimiliano Rossi
, Geneviève Demarquay
, Gaetan Lesca
,
Kern Olofsson
, D A Koolen
, Frauke Hornemann
, Stephanie Baulac
,
Guido Rubboli
, Kelly Q Minks
Bohoon Lee, Ingo Helbig, Dennis Dlugos,
Rikke S Møller
, David Bearden
Show 5 more
Show less
*
Corresponding author for this work
Filadelfia
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
Overview
Fingerprint
Fingerprint
Explore the research areas of 'Treatment Responsiveness in KCNT1-Related Epilepsy'.
Sort by
Weight
Alphabetically
Keyphrases
Quinidine
100%
KCNT1-related Epilepsy
100%
KCNT1
50%
Seizure Reduction
33%
Treatment Efficacy
16%
Effective Therapy
16%
Specific Response
16%
Pathogenic Variants
16%
Seizure Frequency
16%
Seizure Freedom
16%
Clinical Seizure
16%
Precision Medicine
16%
Ketogenic Diet
16%
Blood Levels
16%
Patient Registry
16%
Epileptic Spasms
16%
Vigabatrin
16%
Drug-resistant Epilepsy
16%
Medicine and Dentistry
Quinidine
100%
KCNT1
100%
Epileptic Seizure
66%
Nicotinamide Adenine Dinucleotide Phosphate
33%
Observational Study
16%
Patient Registry
16%
Combination Therapy
16%
Side Effect
16%
Ketogenic Diet
16%
Epileptic Spasms
16%
Vigabatrin
16%
Neuroscience
KCNT1
100%
Quinidine
100%
Nicotinamide Adenine Dinucleotide Phosphate
33%
Ketogenic Diet
16%
Vigabatrin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Quinidine
100%
Nicotinamide Adenine Dinucleotide Phosphate
33%
Combination Therapy
16%
Observational Study
16%
Patient Registry
16%
Side Effect
16%
Vigabatrin
16%
Muscle Spasm
16%